A Phase 4, Double-blind, Randomised, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa
Phase of Trial: Phase IV
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Adalimumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms SHARPS
- Sponsors AbbVie
- 19 Jul 2017 Planned End Date changed from 1 Feb 2020 to 19 Jan 2020.
- 19 Jul 2017 Planned primary completion date changed from 1 Oct 2019 to 2 Oct 2019.
- 24 Jan 2017 Planned End Date changed from 1 Aug 2019 to 1 Feb 2020.